
The CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer study results were recently published in the Journal of Thoracic Oncology.
Natasha B. Leighl, MD; Scott A. Laurie, MD; Glenwood D. Goss, MD; Brett G.M. Hughes, MBBS ; Martin Stockler, MBBS ; Ming-Sound Tsao, MD ; David M. Hwang, MD ; Phillipe Joubert, MD ; Swati Kulkarni, MD ; Normand Blais, MD Anil A. Joy, MD ; Mihaela Mates, MD ; Punam Rana, MD ; Sunil K. Yadav, MD ; Craig Underhill, MBBS ; Christopher Lee, MD ; Penelope A. Bradbury, MB ; Andrea Hiltz, MSc ; Janet Dancey, MD ; Keyue Ding, PhD ; Francisco Vera-Badillo, MD
To access the BR34 Online Publication
In collaboration with the Australian Lung Cancer Trials Group, approximately 300 lung patients from Canada and Australia where treated with a combination immunotherapy and added chemotherapy to half T(randomized to combination IO +/- chemotherapy) as first line treatment in advanced lung cancer patients and was conducted. First-line therapy for patients with metastatic non-small cell lung cancer(NSCLC) includes checkpoint inhibitor monotherapy, dual checkpoint inhibition or in combination with chemotherapy. The study compared outcomes with combination chemo-immunotherapy versus dual checkpoint inhibition as first-line treatment for patients with metastatic NSCLC.
"Through this study we showed that patients did not live longer with chemotherapy so there may be a way forward to selecting more patients for an immunotherapy/chemotherapy-free approach for first-line therapy," says study lead Dr. Natasha B. Leighl at Princess Margaret Cancer Centre.